Heart Failure

The Elecsys NT-proBNP test is an objective biomarker that aids in the diagnosis of individuals believed to have congestive heart failure.

In 2020, heart disease death rates increased in adults across all age, sex, racial and ethnic groups, specifically among younger adults and non-Hispanic Black adults.

However, findings do not preclude the possibility that mechanisms other than cardiac remodeling may be responsible for benefits of SGLT2 inhibition.

Intravenous iron reduced the risk of hospitalization for heart failure or cardiovascular death by approximately 20%.

Experts said the results will likely not alter practice and clinicians will likely continue to use torsemide.

Among heart failure patients, those who were at risk of social isolation had a worse attitude about advance care planning.

The results showed that these participants were more than 27 times as likely to develop VTE, more than 21.5 times as likely to be diagnosed with heart failure, and 17.5 times as likely to have a stroke.

Food insecurity has previously been linked to adverse cardiovascular outcomes, but research is limited regarding the local food environment and the association with death from heart failure.

Black adults are suggested to have an increased risk of heart failure, which highlights the need for equitable treatment and decision-making.

Investigators found that 25% of patients with heart failure with reduced ejection fraction received guideline-recommended intravenous fluids compared to 37% who did not have the condition.

Furosemide injection 80 mg/10 mL (Furoscix; scPharmaceuticals) is indicated for the at-home treatment of congestion caused by fluid overload in adult patients with New York Heart Association Class II/III chronic heart failure.

The combination of loop diuretics with other drugs that act at different pharmacologic targets has been shown to improve diuretic response in patients with heart failure.

New research suggests that acetazolamide and standard loop-diuretic therapy may decrease congestion and prevent future hospitalizations in patients with acute decompensated heart failure.

High intake of refined grains linked to an increased risk of premature coronary artery disease.

Empagliflozin has been found to lower the risk of death due to cardiovascular events and the number of first and recurrent heart failure hospitalizations.

The incremental use of drug combinations could prevent hospitalizations from heart failure among those who have higher ejection farction, a subgroup that struggles with insufficient data on treatments.

Researchers found that patients diagnosed with early-onset type 2 diabetes have a greater risk of premature death than the general population.

Pre-specified pooled analysis from phase 3 trials demonstrates 14% reduction in CV mortality and from any cause by 10% in individuals with HF, irrespective of ejection fraction.

Statins have been found to moderately benefit patients with cardiovascular disease risk factors, but researchers found socioeconomic disparities among those treated with statins.

Researchers find that the risk of developing dementia increased by 35% in patients with atrial cardiopathy.

Early detection of chronic kidney disease is vital to preventing comorbid conditions.

Results also show that no association with an increased frequency of myocarditis, venous thromboembolism, or worsening HF in these individuals.

Treatment with empagliflozin also found to improve cardiac geometry, myocardial mechano-energetic efficiency, and cardiac function.

Insurer and pharmacy benefit manager policies used to cut the cost of drugs could be so time consuming that they could put newly diagnosed atrial fibrillation patients at risk of stroke.

Analysis supports positive lifestyle habits, such as exercising and quitting smoking, investigators say.

Globally, more than 40 million patients are currently taking an ACE inhibitor, primarily for the treatment of high blood pressure and heart failure.

Study finds that only 19.6% of US adults have high cardiovascular health, whereas 62.5% have moderate health and 17.9% have low.

Compared to atorvastatin, rosuvastatin was associated with higher risks of blood in the urine and kidney failure that requires replacement therapy.

Records from 11 million patients shows that non-alcoholic fatty liver disease could increase the risk of developing heart failure by 50%.

Empagliflozin also was associated with Improvement in quality of life and greater reduction in body weight.